About
In 2024, we launched our company to develop a home-use device that utilizes noninvasive ultrasound neuromodulation to reduce chronic migraine symptoms. Our technology aims to address the shortcomings of existing treatments like migraine medications with harsh side effects and the limited effectiveness of current devices. Our core team has a decade of experience in engineering ultrasound neuromodulation devices and studying their clinical effects. This combined with in-house R&D and engagement with chronic migraine sufferers has led us to develope the optimal home-use device. We are currently at the human testing stage and seeking funding for further testing. Please reach out for more information if you are interested in financially supporting our efforts.
Technologies
Keywords
Company Information
-
Employees 1
-
Founded 2024
Location
New York, New York, United States
